{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:03:19Z","timestamp":1774548199997,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Colloids and Surfaces B: Biointerfaces"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.colsurfb.2011.03.035","type":"journal-article","created":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T19:52:37Z","timestamp":1304279557000},"page":"158-165","source":"Crossref","is-referenced-by-count":248,"title":["Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): High pressure homogenization versus ultrasound"],"prefix":"10.1016","volume":"86","author":[{"given":"A.C.","family":"Silva","sequence":"first","affiliation":[]},{"given":"E.","family":"Gonz\u00e1lez-Mira","sequence":"additional","affiliation":[]},{"given":"M.L.","family":"Garc\u00eda","sequence":"additional","affiliation":[]},{"given":"M.A.","family":"Egea","sequence":"additional","affiliation":[]},{"given":"J.","family":"Fonseca","sequence":"additional","affiliation":[]},{"given":"R.","family":"Silva","sequence":"additional","affiliation":[]},{"given":"D.","family":"Santos","sequence":"additional","affiliation":[]},{"given":"E.B.","family":"Souto","sequence":"additional","affiliation":[]},{"given":"D.","family":"Ferreira","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.colsurfb.2011.03.035_bib0005","first-page":"62","article-title":"Solid lipid nanoparticles (SLN)\u2014an alternative colloidal carrier system for controlled drug delivery","volume":"41","author":"M\u00fcller","year":"1995","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery\u2014a review of the state of the art","volume":"50","author":"M\u00fcller","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0015","unstructured":"M.R. Gasco, Method for producing solid lipid microspheres having a narrow size distribution, United States of America Patent, 1993."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0020","first-page":"743","article-title":"Oral insulin delivery by means of solid lipid nanoparticles","volume":"2","author":"Sarmento","year":"2007","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0025","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0378-5173(03)00070-X","article-title":"Interactions of solid lipid nanoparticles with model membranes and leukocytes studied by EPR","volume":"256","author":"Kristl","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0030","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijpharm.2008.07.028","article-title":"Cyclosporineo A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity","volume":"364","author":"Gokce","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0035","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/03639040500216329","article-title":"Characterization and body distribution of beta-elemene solid lipid nanoparticles (SLN)","volume":"31","author":"Wang","year":"2005","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijpharm.2006.07.026","article-title":"Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin","volume":"327","author":"Zhang","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0045","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/03639040701662230","article-title":"Preparation and characterization of 10-hydroxycamptothecin loaded nanostructured lipid carriers","volume":"34","author":"Liu","year":"2008","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0050","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","article-title":"Solid lipid nanoparticles: production, characterization and applications","volume":"47","author":"Mehnert","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0055","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.addr.2003.12.002","article-title":"Solid lipid nanoparticles for parenteral drug delivery","volume":"56","author":"Wissing","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0060","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0924-977X(03)00109-3","article-title":"A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia","volume":"14","author":"Bhanji","year":"2004","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0065","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/070674370404901009","article-title":"Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder","volume":"49","author":"Chue","year":"2004","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0070","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2004.03.001","article-title":"Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system","volume":"58","author":"Lindenberg","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0075","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.addr.2007.10.014","article-title":"Enhancing intestinal drug solubilisation using lipid-based delivery systems","volume":"60","author":"Porter","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0080","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ultsonch.2006.10.007","article-title":"Cavitation\u2014a novel technique for making stable nano-suspensions","volume":"14","author":"Patil","year":"2007","journal-title":"Ultrason. Sonochem."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0085","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0939-6411(98)00074-5","article-title":"Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase","volume":"47","author":"Freitas","year":"1999","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0090","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.colsurfb.2009.03.007","article-title":"Turbiscan lab expert analysis of the stability of ethosomes and ultradeformable liposomes containing a bilayer fluidizing agent","volume":"72","author":"Celia","year":"2009","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0095","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0039-9140(99)00129-0","article-title":"TURBISCAN MA 2000: multiple light scattering measurement for concentrated emulsion and suspension instability analysis","volume":"50","author":"Mengual","year":"1999","journal-title":"Talanta"},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0105","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF00756522","article-title":"The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications","volume":"11","author":"Meunier","year":"1995","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0110","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003495-199448020-00009","article-title":"Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia","volume":"48","author":"Grant","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0115","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijpharm.2006.02.045","article-title":"Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals","volume":"317","author":"M\u00fcller","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0120","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ejpb.2007.07.006","article-title":"Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation","volume":"68","author":"M\u00fcller","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0125","first-page":"508","article-title":"Physicochemical investigations on the structure of drug-free and drug-loaded solid lipid nanoparticles (SLN) by means of DSC and 1H NMR","volume":"60","author":"Zimmermann","year":"2005","journal-title":"Pharmazie"},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0130","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijpharm.2005.02.005","article-title":"Preparation and characterization of n-dodecyl-ferulate-loaded solid lipid nanoparticles (SLN)","volume":"295","author":"Souto","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0135","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1476-511X-8-6","article-title":"Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies","volume":"8","author":"Bhaskar","year":"2009","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0140","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.micron.2007.06.010","article-title":"Scanning electron microscopy study on nanoemulsions and solid lipid nanoparticles containing high amounts of ceramides","volume":"38","author":"Hatziantoniou","year":"2007","journal-title":"Micron"},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0145","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejpb.2010.05.003","article-title":"Non-destructive methods of characterization of risperidone solid lipid nanoparticles","volume":"76","author":"Rahman","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jconrel.2006.05.010","article-title":"Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability","volume":"114","author":"Luo","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0155","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.addr.2007.04.013","article-title":"Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering","volume":"59","author":"Bunjes","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0160","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.colsurfb.2010.07.029","article-title":"Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC","volume":"81","author":"Gonzalez-Mira","year":"2010","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0165","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1021\/la062904p","article-title":"Visualizing the structure of triglyceride nanoparticles in different crystal modifications","volume":"23","author":"Bunjes","year":"2007","journal-title":"Langmuir"},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0170","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1023\/A:1012043315093","article-title":"Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant","volume":"14","author":"M\u00fcller","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0175","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejpb.2010.02.014","article-title":"A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung","volume":"75","author":"Nassimi","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0180","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/10611869609015973","article-title":"Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407","volume":"4","author":"M\u00fcller","year":"1996","journal-title":"J. Drug Target."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0185","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijpharm.2009.07.036","article-title":"Monoglyceride-based self-assembling copolymers as carriers for poorly water-soluble drugs","volume":"382","author":"Rouxhet","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2011.03.035_bib0190","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0378-5173(96)04539-5","article-title":"Cytotoxicity of magnetite-loaded polylactide, polylactide\/glycolide particles and solid lipid nanoparticles","volume":"138","author":"M\u00fcller","year":"1996","journal-title":"Int. J. Pharm."}],"container-title":["Colloids and Surfaces B: Biointerfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776511001822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776511001822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T22:36:32Z","timestamp":1583966192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0927776511001822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0927776511001822"],"URL":"https:\/\/doi.org\/10.1016\/j.colsurfb.2011.03.035","relation":{},"ISSN":["0927-7765"],"issn-type":[{"value":"0927-7765","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}